About the Event
Heart Rate Variability (HRV) testing was developed by Omegawave to help world-class athletes recover more quickly and perform at their peak. Inmedix has an exclusive license to use this technology in healthcare.
Inmedix has adapted the next generation of HRV testing to measure stress biology as a diagnostic aid across a variety of conditions including rheumatology. The total addressable market for this breakthrough exceeds $3BN.
Join our panel discussion to learn about the genesis of the technology and hear how Inmedix plans to roll out their HRV platform that 96% of rheumatologists surveyed say they need now.
Featured Panelists:
Dr. Andrew Holman, Founder and CEO, Inmedix
Andrew is the founding rheumatologist and Director of Research at Pacific Rheumatology Research Inc. He is former President of the Northwest Rheumatism Society and a Clinical Associate Professor of Medicine at the University of Washington. He has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.
Leslie Bottorff, Principal, Bottorff Advisors
Leslie works with CEOs and teams of MedTech companies to build new products and accelerate growth. She was Sr. Managing Director at GE Ventures where she led the healthcare investing team and an operating executive in the medical device industry. She has an MBA from Harvard Business School and an Engineering degree from Purdue University.
Val Nasedkin, VP, Omegawave
Val is one of the developers of Omegawave technology and the company’s VP of Business Development. He is an expert in physiological readiness as well as a former elite athlete and a current coach. He is also in the advisory board for the Nike Sparq athletic performance division.
